News

ACADIA Pharmaceuticals Inc., a biopharmaceutical company specialized in the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, has just announced it has filed for a New Drug Application with the US Food and Drug Administration for NUPLAZID (pimavanserin) for the treatment of psychosis associated…

A study entitled “High rates of parkinsonism in adults with autism”, published 30 August, 2015 in the Journal of Neurodevelopmental Disorders, has established a correlation between autism and parkinsonian motor signs. Autism spectrum disorder (ASD) is diagnosed in approximately 1.5% of children in the…

Researchers from the University of Maryland Medicine and from its Center for Metabolic Imaging and Image-Guided Therapeutics (CMIT) are conducting the first clinical trial with ultrasound waves to treat Parkinson’s disease (PD) patients. Using magnetic resonance imaging (MRI), they guide ultrasound waves through the intact skin and skull to a deep brain…

Neuroscientists from the University of Adelaide are leading a first-of-its-kind study on a type of dementia commonly observed in patients with Parkinson’s disease, which the scientists hope lead to a potential new therapy. From September 1-7, 2015, during the Parkinson’s Awareness Week, the University of Adelaide’s School of Medicine’s Dr. Lyndsey Collins-Praino will be…

The National Parkinson Foundation’s (NPF) medical director, Michael S. Okun, M.D., recently published a new book, titled, “10 Breakthrough Therapies for Parkinson’s Disease,” which is a follow-up of his previous Amazon bestseller “Parkinson’s Treatment: 10 Secrets to a Happier Life.” The sequel provides updated information to patients and their…

In a new study entitled “Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons” scientists discovered why dopamine producing neurons are particularly vulnerable in Parkinson’s disease. These new findings point towards a key role for mitochondria and these neurons’ high energy requirements…

Researchers at Università degli Studi di Perugia and Ospedale Santa Maria della Misericordia in Italy recently published an article entitled “The changing tree in Parkinson’s disease” in the journal Nature Neuroscience. This report focused on recent findings, entitled “Dynamic rewiring…

The Lawson Health Research Institute recently signed a licensing agreement with STEMCELL Technologies to transfer international exclusive rights to commercialize innovative tools for Parkinson’s Disease research. STEMCELL Technologies provides more than 2,000 products to over 70 countries worldwide, including cell culture reagents, instruments and tools designed to support science along the basic to translational…

This week, Massachusetts Institute of Technology (MIT) researcher, Ann M. Graybiel, Ph.D. whose laboratory is part of MIT’s McGovern Institute for Brain Research and is focused on studying brain structures that are important for normal brain function but are also implicated in Parkinson’s disease, released results from a study…

In a new study entitled “VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson’s Disease” scientists discovered that loss of the VPS35 protein expression in Parkinson’s disease interferes…